CurrentUnitedHealthcarePolicy CSIND0073.03

Self-Administered Medications (for Indiana Only)

Defines which medications are considered self-administered and not reimbursed under the medical benefit for UnitedHealthcare members in Indiana.

Policy Summary

PayerUnitedHealthcare

PolicySelf-Administered Medications (for Indiana Only)

Policy CodePolicy CSIND0073.03

Change TypeNo content changes

Effective DateNov 1, 2025

Next Review Date

Key ActionRefer to the Self‑Administered Medications List for applicable HCPCS codes to determine whether a drug is designated as self‑administered and therefore not reimbursed on the medical benefit.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

State-specificPolicy applies to

0637Revenue code

No content changesRevision note

MultipleDesignation factors

Coverage Criteria — Self‑Administered Medications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Self‑administration criteria: Medication is not typically administered or directly supervised by a qualified provider or licensed/certified health professional in an outpatient setting; and Medication does not require continuous or periodic monitoring immediately before, during, or after administration by a qualified provider or licensed/certified health professional in an outpatient setting; and Route of administration (e.g., oral, inhaled, intranasal, topical, rectal, subcutaneous, or self‑injectable intramuscular injections); and Dosage form (e.g., prefilled syringe, auto‑injector, tablet, capsule, suppository, nasal spray, metered dose inhaler, nebulized solution); and Acuity of condition (e.g., chronic disease); and Frequency of administration; and Standards of medical practice allowing for self‑administration (e.g., self‑infused hemophilia factor); and Evaluation of established medical literature or compendia including FDA approved prescribing information, manufacturer provided medical literature, peer‑reviewed medical literature, evidence‑based practice guidelines, self‑administration utilization statistics, and compendia (e.g., IBM Micromedex DRUGDEX, Clinical Pharmacology).

All listed factors are considered when designating a medication as self‑administered.

Any applicable clinician‑administered dosage formulations (for example, intravenous infusion) of drugs that appear on the Self‑Administered Medications List may be considered separately for coverage under the medical benefit. Refer to the Self‑Administered Medications List (for Indiana only) to determine which HCPCS codes correspond to medications designated as self‑administered and to identify clinician‑administered formulations that may remain eligible for medical benefit reimbursement.

Provider Actions & Billing Guidance

Denial Risk

Denial Risk — Self‑Administered Medications

Provider action: Verify whether the medication is designated as self‑administered. If so, do not bill the medication to the medical benefit; the claim may be denied. For medications on the Self‑Administered Medications List, use the corresponding HCPCS/NDC billing guidance for pharmacy or member‑directed coverage.

Medications designated as self‑administered are not reimbursed on medical benefit plans — denial risk if billed to medical benefit.
Check the Self‑Administered Medications List (Indiana Only) to identify applicable HCPCS codes and determine the correct billing pathway.
If a clinician‑administered dosage formulation exists for the same drug (e.g., IV infusion), bill the clinician‑administered formulation under the medical benefit when appropriate and documented.

Billing Rule

Medical vs. Self‑Administered Coding

Billing rule: Distinguish self‑administered formulations from clinician‑administered formulations. Only clinician‑administered dosage forms (for example, IV infusion) that are documented as administered by a qualified provider should be billed to the medical benefit.

Refer to the Self‑Administered Medications List for applicable HCPCS codes corresponding to medications determined to be self‑administered.
Any clinician‑administered dosage formulations of drugs on the Self‑Administered Medications List may be covered under the medical benefit when appropriately documented.
When billing clinician‑administered formulations, include documentation of administration (route, setting, supervising provider) to support medical benefit payment.

Prior Authorization

Provider Action

Provider action / alert: Prior to claim submission, confirm the drug formulation and route of administration and consult the Self‑Administered Medications List. Where uncertainty exists, obtain prior authorization or clinical documentation that clearly supports clinician administration to avoid denial.

Confirm formulation (e.g., prefilled syringe vs. IV bag) and route (e.g., subcutaneous vs. intravenous) in the medical record.
Document continuous or periodic monitoring requirements if claiming clinician administration.
If in doubt, request prior authorization or payer guidance before billing to medical benefit.

Note

Coding Reference — Self‑Administered Medications List

Refer to the Self‑Administered Medications List (for Indiana Only) for the official listing of medications determined to be self‑administered and the applicable HCPCS codes to be used for pharmacy or member‑directed billing.

Self‑Administered Medications List (for Indiana Only) — contains HCPCS mappings and designation rationale.
Use the listed HCPCS codes when the medication is determined to be self‑administered; do not submit those codes on a medical benefit claim unless a clinician‑administered formulation is used and documented.

Background

Medications are designated as self‑administered when all listed factors indicate they can be safely and appropriately administered by the patient without direct supervision by a qualified provider. Factors considered include whether the medication is typically administered or directly supervised in an outpatient setting, whether it requires continuous or periodic monitoring immediately before, during, or after administration, the route of administration (for example, oral, inhaled, intranasal, topical, rectal, subcutaneous, or self‑injectable intramuscular), the dosage form (for example, prefilled syringe, auto‑injector, tablet, capsule, suppository, nasal spray, metered dose inhaler, nebulized solution), the acuity and frequency of treatment, standards of medical practice that allow self‑administration, and review of established medical literature and compendia (including FDA prescribing information, manufacturer literature, peer‑reviewed literature, evidence‑based guidelines, utilization statistics, and compendia such as IBM Micromedex DRUGDEX and Clinical Pharmacology). These combined considerations form the rationale for excluding self‑administered medications from medical benefit reimbursement.

Definitions

Self‑administered drugs — definition and criteria

DefinitionMedications administered by the patient that do not require direct supervision by a qualified provider or licensed/certified health professional.

Key indicatorsNot typically administered or directly supervised by a qualified provider in an outpatient setting; does not require continuous or periodic monitoring immediately before, during, or after administration.

Routes / dosage formsIncludes oral, inhaled, intranasal, topical, rectal, subcutaneous, self-injectable intramuscular; dosage forms such as prefilled syringe, auto-injector, tablet, capsule, suppository, nasal spray, metered dose inhaler, nebulized solution.

Clinical context consideredAcuity of condition (e.g., chronic disease), frequency of administration, and standards of medical practice allowing self-administration (e.g., self-infused hemophilia factor).

Evidence reviewDetermination includes evaluation of FDA prescribing information, manufacturer literature, peer-reviewed literature, evidence-based guidelines, utilization statistics, and compendia (e.g., IBM Micromedex DRUGDEX, Clinical Pharmacology).

Coverage implicationDesignated self-administered drugs are not reimbursed under the medical benefit for UnitedHealthcare members in Indiana.

Site of Care — Where Self‑Administration Applies